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Our cohort have a calving peak between 
November and February, so most cases of first 
trimester occurred between January and April, 
the peak of incidence remains the second 













Rear quarters had significantly lower TC 
(p<0,05%). Grade 3 mastitis had lower TC, 
42,6% (p<0.05%) versus 48,9 % for grade 2 
and 44,2% for grade 1. Almost 47% of all 
mastitis was considered as chronic cases. 
Indeed, TC was lower on cases from more than 
4 month in milk, third lactation (OR = 2.8 for no 
cure) compared with previous, and chronic 
cases (OR=2,6). Seemingly, chronicity was 
positively associated with parity and season. 
The 3rd parity cases had higher chances to be 
chronic ones (OR = 1,7), as well as cases from 
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INTRODUCTION 
Mastitis is the most “antibiotic consuming” pathology in dairy medicine. Though 
antibiotics and antibiograms are known to vets since the early fifties, our practices did not 
evolved a lot from empiric antibiotic therapy [2]. Nevertheless, there is a surge for rational 
use of antibiotics. Since 2010 in southern Belgium, an integrated document called “Udder 
Health File” (UHF, Fig. 1) is sent to farmers participating in the project  LAECEA (“milk” in local 



















So far 1194 mastitis treatment events were recorded in the 30 farms participating the research project 
[3]. In order to evaluate mastitis treatment strategies, we chose to compare tissular cure (TC) based 
on the threshold of 200.000 somatic cells/ml in milk at milk control at least 60 days after the 
clinical mastitis event, It was considered a new case a cow which at least 15 days before had an 
SCC <200.000 cells/ml, other were marked as chronic cases. 
This work was funded by grants from the Walloon Ministry of Agriculture. All research projects on mastitis in Wallonia are 
discussed by participants of the Observatory for Udder Health (OSaM). 
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RESULTS & DISCUSSION 
  
Our mastitis cohort (1194 cases) revealed different known 
characteristics in western countries like a peak of incidence from January 
to May, and posterior quarters tended to be more affected by clinical 
cases. Treatment constituted most of the time in Intramammary tubes 
associated or not with a parenteral antibiotic, anti-inflammatory drug were 
used in 10% of cases (Fig. 3). We also noted that most clinical cases are 
either grade 1 or 2 mastitis, severe cases representing 10% of all 
recordings, subclinical mastitis treatment is not very spread in Belgium, 





















While refining data with treatment 
protocol, it could be frustrating because or 
the different routes and molecules used, that 
weakens the comparison. Nevertheless, it 
was underlined that 4th generation 
cephalosporins (C4G) were the most 
used in our cohort, followed by 
aminopenicillin/methicillin association 
(PENA/PENM) and 1st generation 
cephalosporins/aminoglycosids (C1G/AG) 
association. Of these intramammary 
treatments, 20% of the cases were 
submitted to a second intramammary drug, 
mostly C1G or C1G/AG. Parenterally treated 
cases were administered mostly macrolids, 
fluoroquinolones and penethacillin. 
Finally, most used anti-inflammatory drugs 


















Use of a parenteral injections increased 
TC only on new cases (+12%), but not on 
chronic cases. Refining by severity, TC 
improved with a parenteral on new cases, 




















It is interesting to note that combination 
of AI and parenteral AB are associated 












Best cure rates according to IMM use, 
with no parenteral AB nor AI were achieved 
by  C1G/AG, PENA/PENM associations, 
and Prednisolone containing products 
(CASCADE),  reaching more than 50% of 
cure.  
Figure 1: Economic control panel of the Udder Health File summing-up all losses linked to mastitis. In yellow the loss due to Culling, death or quarter 
losses; in orange the penalties for bad milk quality; in grey the mastitis treatments and in red the subclinical losses due to cell counts. The black line 
reminds the “tolerable losses” according to a fair rate of mastitis, either clinical or subclinical. At the bottom right, the total loss per cow per year of this 
farm is 187 euros, where the tolerable level is around 70€/cow/year. 
B. Analyzing Cure rates according to time/seasonality, cellular history and animal 
characteristics 
A. Characteristics of clinical mastitis in the cohort 
Figure 3: Distribution of treatments combinations (IMM: 
intramammary route ; P : parenteral route AB; AI : Use of Anti-
inflammatory drug in parenteral administration) 
C. Analyzing cure rates according to treatment type and molecule 
Cross-sectional analysis of health data is always challenging, because of  the variety 
of data, the bias and the data loss. However, these data have shown that use of 
antibiotics in mastitis is around 80%, with less than 60% chance of reaching good 
somatic cell counts afterwards. With a simple look at DHI data, a mastitis could be better 
managed in an in-farm protocol [4].  
It is interesting that most efficient molecules are wide spectrum association or 
steroidal anti-inflammatory combination; along with the increased cure rates observed 
when using parenteral AI. These results underlines the question of the management of 
inflammation in mastitis, which is not well accounted for [2], as well as Gram negative 
infection risk in lactation rather than just post-partum.  
Future recommendations over the limitations of AB use should therefore include 
epidemiological alerts for the risk of chronic cases, least susceptible to be correctly 
treated, and also alternatives in the treatment protocol, such as focusing on inflammation 
rather than only infection of the quarters. 
CONCLUSION 
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Figure 4: Distribution of mastitis severity in the database 
(1 : alteration of milk; 2 udder swollen/painful; 3 general 
signs like anorexia, hyperthermia or recumbency; 4 : 
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Days in milk 







































































Percentage of animals cured after 60 days 
Figure 6: Variation of TC at 60 days depending on various factors 
relative to the clinical case, the cow or the time. The overall cure rate 
is in plain green. Each variable has a maximum cure rate in hatched 
green. In our cohort, primiparous cows achieved better cure rates for 





















Figure 7: Use of intramammary antibiotics according to molecules 
and associations (C4G= 4th generation cephalosporin, PENA/PENM 
= aminopenicilline/methicilline, C1G/AG = 1st generation 
cephalosporine/Aminoglycoside ; MACR = Macrolids ;  HOMEO = 
non veterinary labelled drugs phyto/homeo ; C1G = 1st generation 
cephalosporine, PENM = Methicilline, C3G = 3rd gen. cephalosporin, 



















Figure 8: Impact of a parenteral antibiotic according to chronicity of 
the case 
Combination 
Odds-ratio for  
no cure 
p-value 
IMM+AI  0,74 p<0,05 
IMM+P 0,75 p<0,05 
IMM+P+AI 0,49 p<0,05 
IMM+P+AI on new cases 0,61 p<0,05 
IMM+P+AI on chronic 0,42 p<0,05 
Table I: Association of combination of AI and Parenteral AB effect on 
cure rates.   
